TRIPLET THERAPIES OF HDAC INHIBITORS, PD-L1 AND/OR PD-1 INHIBITORS, AND CTLA-4 INHIBITORS
Provided herein is a combination therapy comprising an HDAC inhibitor (HDACi) a PD-L1 and/or a PD-1 inhibitor, and a CTLA-4 inhibitor. The combination therapy provided herein can be a kit or the composition or a pharmaceutical composition. Also, provided herein is a method of treating cancer using the combination therapy.
1 . A combination comprising a therapeutically effective amount of a PD-L1 inhibitor, a PD-1 inhibitor, a CTLA-4 inhibitor, a CD276 inhibitor, a therapeutically effective amount of a compound of formula I, or pharmaceutically acceptable salt or solvate thereof, or any combination thereof, wherein formula I is:
wherein,
A is phenyl or a heterocyclic group, optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkythio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, C 1 -C 4 alkoxycarbonyl, phenyl, and a heterocyclic group;
B is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkylthio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, C 1 -C 4 alkoxycarbonyl, and phenyl;
Y is a moiety comprising —CO— which is linear and in which the distances between the centroid of ring B (W1), the centroid of ring A (W2) and an oxygen atom as a hydrogen bond acceptor in the moiety Y (W3) are: W1-W2=about 6.0 Å, W1-W3=about 3.0 Å to about 6.0 Å, and W2-W3=about 4.0 Å to about 8.0 Å, respectively;
Z is a bond or C 1 -C 4 alkylene, —O—, —S—, —NH—, —CO—, —CS—, —SO—, or —SO 2 —;
R 1 and R 2 are independently hydrogen or C 1 -C 4 alkyl;
R 3 is hydrogen or C 1 -C 4 alkyl;
R 4 is hydrogen or —NH 2 ;
one of X 1 , X 2 , X 3 , or X 4 is halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkylthio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, or C 1 -C 4 alkoxycarbonyl optionally substituted with halogen or C 1 -C 4 alkyl, while the others of X 1 , X 2 , X 3 , or X 4 are independently hydrogen,
provided that when R 4 is hydrogen, one of X 1 , X 2 , X 3 , or X 4 is —NH 2 , an aminoalkyl group or an alkylamino group.
2 . The combination of claim 1 , wherein said compound of formula I has the structure of formula Ia:
or a pharmaceutically acceptable salt or solvate thereof.
3 . The combination of claim 1 , wherein said compound of formula I is N-(2-amino-4-fluorophenyl)-4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]benzamide.
4 . The combination of claim 1 , wherein said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor is a small molecule compound, a nucleic acid, a peptide, a protein, an antibody, a peptibody, a diabody, a minibody, a single-chain variable fragment (ScFv), or a fragment or variant thereof.
5 . The combination of claim 4 , wherein at least one of said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor is an antibody.
6 . The combination of claim 5 , wherein said inhibitor antibody is a monoclonal antibody.
7 . The combination of claim 5 or 6 , wherein said inhibitor antibody comprises a human antibody, a mouse antibody, a chimeric antibody, a humanized antibody, or a chimeric humanized antibody.
8 . The combination of one of claims 5 to 7 , wherein said inhibitor antibody is a human antibody or a humanized antibody.
9 . The combination of one of claims 5 to 8 , wherein said inhibitor antibody is present at an amount of about 0.1 mg/kg to about 30 mg/kg.
10 . The combination of one of claims 5 to 9 , wherein said inhibitor antibody is present at an amount of about 0.5 mg/kg to about 15 mg/kg.
11 . The combination of one of claims 5 to 10 , wherein said inhibitor antibody is present at an amount of about: 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 2 mg/kg, 2.5 mg/kg, 3 mg/kg, 5 mg/kg, 10 mg/kg, or 20 mg/kg.
12 . The combination of any one of claims 1 to 11 , wherein said combination is suitable for parenteral administration to a cancer patient.
13 . The combination of claim 12 , wherein said parenteral administration comprises intravenous (IV) administration.
14 . A pharmaceutical composition comprising a combination of any one of claims 1 to 13 and a pharmaceutically acceptable excipient.
15 . A kit comprising the combination of any of one of claims 1 to 13 or a pharmaceutical composition of claim 14 .
16 . The kit of claim 15 , further comprising at least one administration device.
17 . The kit of claim 15 or 16 , wherein components in the kit are sterilized.
18 . A method for treating cancer, said method comprising administering a therapeutically effective amount of a combination of any one of claims 1 to 13 or a pharmaceutical composition of claim 14 to a subject in need thereof.
19 . The method of claim 18 , wherein said subject has a mutated BRAF gene.
20 . The method of claim 18 or 19 , wherein said cancer is a solid tumor cancer selected from the group consisting of squamous cell carcinoma, nonsquamous cell carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, melanoma, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, head and neck cancer, urothelial cancer, breast cancer, prostate cancer, glioblastoma, colorectal cancer, pancreatic cancer, lymphoma, leiomyosarcoma, liposarcoma, synovial sarcoma, or malignant peripheral sheath tumor (MPNST).
21 . The method of claim 20 , wherein said cancer is non-small cell lung cancer (NSCLC), hepatocellular carcinoma, melanoma, ovarian cancer, breast cancer, pancreatic cancer, renal cell carcinoma, or colorectal cancer.
22 . The method of claim 20 , wherein said cancer is lymphoma, Non-Hodgkin's lymphoma (NHL), Hodgkin's Lymphoma, Reed-Sternberg disease, multiple myeloma (MM), acute myelogenous leukemia (AML), chronic myelogenous leukemia (CIVIL), acute lymphocytic leukemia, (ALL), or chronic lymphocytic leukemia (CLL).
23 . The method of any one of claims 18 to 21 , wherein said cancer patient is treatment naïve.
24 . The method of claim 22 , wherein said cancer patient is treatment naïve for non-small cell lung cancer (NSCLC), hepatocellular carcinoma, melanoma, ovarian cancer, breast cancer, pancreatic cancer, renal cell carcinoma, or colorectal cancer.
25 . The method of any one of claims 18 to 24 , wherein said combination is administered to said cancer patient as a first line therapy.
26 . The method of any one of claims 18 to 24 , wherein said combination is administered to said cancer patient as a second, third, fourth, fifth, or sixth line of treatment.
27 . The method of any one of claims 18 to 24 , wherein said combination is administered to said cancer patient following treatment with at least one anti-cancer therapy.
28 . The method of claim 27 , wherein said anti-cancer therapy comprises chemotherapy, radiotherapy, surgery, targeted therapy, immunotherapy, or a combination thereof.
29 . The method of any one of claims 18 to 28 , wherein said cancer is resistant to at least one anti-cancer agent.
30 . The method of any one of claims 18 to 29 , wherein said compound of formula I and said inhibitor of said combination are administered simultaneously or sequentially.
31 . The method of any one of claims 18 to 30 , wherein said compound of formula I is administered 2 to 3 times per week.
32 . The method of any one of claims 18 to 31 , wherein said compound of formula I is administered daily.
33 . The method of any one of claims 18 to 32 , wherein said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor and said compound of formula I are concomitantly administered on day 1 of an administration regimen.
34 . The method of claims 18 to 33 , wherein said combination is administered to said patient as a regimen.
35 . The method of claim 34 , wherein said regimen is repeated until disease progression or unacceptable toxicity.
36 . The method of claim 34 , wherein said regimen comprises a rest period of at least 1 day between consecutive administration periods.
37 . The method of any one of claims 18 to 36 , wherein said compound of formula I of said combination is administered 2 to 3 times per week in said regimen and said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor is administered every 2 to 3 weeks.
38 . The method of claim 37 , wherein said compound of formula I of said combination is administered once a day (“QD”) for 21 days in said regimen and said inhibitor antibody is administered every 2 to 3 weeks.
39 . The method of any one of claims 18 to 38 , wherein said method of treating cancer inhibits metastasis of said cancer in said patient.
40 . The method of any one of claims 18 to 39 , wherein said method of treating cancer reduces tumor or tumor burden in said patient.
41 . The method of any one of claims 18 to 40 , wherein said method of treating cancer inhibits pre-existing metastasis of said cancer in said patient.
42 . The method of any one of claims 18 to 41 , wherein said method of treating cancer prolongs the time to disease progression of said cancer in said patient.
43 . The method of any one of claims 18 to 42 , wherein said method of treating cancer prolongs the survival of said patient.
44 . The method of any one of claims 18 to 43 , wherein said method of treating cancer increases progression-free survival of said patient.
45 . A method for treating cancer comprising administering a therapeutically effective amount of a combination of a histone deacetylase inhibitor (HDAC inhibitor) and a PD-L1 inhibitor and/or a PD-1 inhibitor, plus a CTLA-4 inhibitor, to a subject in need of treatment and whose cancer has been previously treated with a checkpoint inhibitor.
46 . A method for treating cancer comprising administering a therapeutically effective amount of a PD-L1 inhibitor, a PD-1 inhibitor, a CTLA-4 inhibitor, a CD276 inhibitor, a histone deacetylase inhibitor (HDAC inhibitor), or any combination thereof, to a subject in need of treatment and whose cancer has been previously treated with a checkpoint inhibitor.
47 . A method for treating cancer comprising administering a therapeutically effective amount of a PD-L1 inhibitor, a PD-1 inhibitor, a CTLA-4 inhibitor, a CD276 inhibitor, a histone deacetylase inhibitor (HDAC inhibitor), or any combination thereof, to a subject in need of treatment wherein said subject comprises a mutated BRAF gene.
48 . A method for treating cancer comprising administering a therapeutically effective amount of:
(a) a compound of formula I, or a pharmaceutically acceptable salt or solvate thereof; wherein formula I is:
wherein,
A is phenyl or a heterocyclic group, optionally substituted with 1 to 4 substituents selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkythio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, C 1 -C 4 alkoxycarbonyl, phenyl, and a heterocyclic group;
B is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkylthio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, C 1 -C 4 alkoxycarbonyl, and phenyl;
Y is a moiety comprising —CO— which is linear and in which the distances between the centroid of ring B (W1), the centroid of ring A (W2) and an oxygen atom as a hydrogen bond acceptor in the moiety Y (W3) are: W1-W2=about 6.0 Å, W1-W3=about 3.0 Å to about 6.0 Å, and W2-W3=about 4.0 Å to about 8.0 Å, respectively;
Z is a bond or C 1 -C 4 alkylene, —O—, —S—, —NH—, —CO—, —CS—, —SO—, or —SO 2 —;
R 1 and R 2 are independently hydrogen or C 1 -C 4 alkyl;
R 3 is hydrogen or C 1 -C 4 alkyl;
R 4 is hydrogen or —NH 2 ;
one of X 1 , X 2 , X 3 , or X 4 is halogen, —OH, —NH 2 , —NO 2 , —CN, —COOH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy, C 1 -C 4 aminoalkyl, C 1 -C 4 alkylamino, C 2 -C 4 acyl, C 2 -C 4 acylamino, C 1 -C 4 alkylthio, C 1 -C 4 perfluoroalkyl, C 1 -C 4 perfluoroalkyloxy, or C 1 -C 4 alkoxycarbonyl optionally substituted with halogen or C 1 -C 4 alkyl, while the others of X 1 , X 2 , X 3 , or X 4 are independently hydrogen, provided that when R 4 is hydrogen, one of X 1 , X 2 , X 3 , or X 4 is —NH 2 , an aminoalkyl group or an alkylamino group; and
(b) one or more inhibitor antibodies, wherein said one or more inhibitor antibodies comprise a PD-L1 inhibitor, a PD-1 inhibitor, a CTLA-4 inhibitor, a CD276 inhibitor, or any combination thereof, and wherein said one or more inhibitor antibodies are present at an amount of about 0.1 mg/kg to about 30 mg/kg;
to a subject in need of treatment.
49 . The method of claim 48 , wherein said compound of formula I, has the structure of formula Ia.
or a pharmaceutically acceptable salt or solvate thereof.
50 . The method of claim 48 , wherein said compound of formula I is N-(2-amino-4-fluorophenyl)-4-[[[(2E)-1-oxo-3-(3-pyridinyl)-2-propen-1-yl]amino]methyl]benzamide.
51 . The method of any one of claims 48 to 50 , wherein said one or more inhibitor antibodies are monoclonal antibodies.
52 . The method of any one of claims 48 to 51 , wherein said one or more inhibitor antibodies comprise a human antibody, a mouse antibody, a chimeric antibody, a humanized antibody, or a chimeric humanized antibody.
53 . The method of any one of claims 48 to 52 , wherein said inhibitor antibody is a human antibody or a humanized antibody.
54 . The method of any one of claims 48 to 53 , wherein said cancer is a solid tumor cancer selected from the group consisting of squamous cell carcinoma, nonsquamous cell carcinoma, non-small cell lung cancer (NSCLC), small cell lung cancer, melanoma, hepatocellular carcinoma, renal cell carcinoma, ovarian cancer, head and neck cancer, urothelial cancer, breast cancer, prostate cancer, glioblastoma, colorectal cancer, pancreatic cancer, lymphoma, leiomyosarcoma, liposarcoma, synovial sarcoma, or malignant peripheral sheath tumor (MPNST).
55 . The method of any one of claims 48 to 54 , wherein said cancer patient is treatment naïve.
56 . The method of claim 55 , wherein said cancer patient is treatment naïve for non-small cell lung cancer (NSCLC), hepatocellular carcinoma, melanoma, ovarian cancer, breast cancer, pancreatic cancer, renal cell carcinoma, or colorectal cancer.
57 . The method of any one of claims 48 to 56 , wherein said combination is administered to said cancer patient as a first line therapy.
58 . The method of any one of claims 48 to 56 , wherein said combination is administered to said cancer patient as a second, third, fourth, fifth, or sixth line of treatment.
59 . The method of any one of claims 48 to 56 , wherein said combination is administered to said cancer patient following treatment with at least one anti-cancer therapy.
60 . The method of claim 59 , wherein said anti-cancer therapy comprises chemotherapy, radiotherapy, surgery, targeted therapy, immunotherapy, or a combination thereof.
61 . The method of any one of claims 48 to 60 , wherein said cancer is resistant to at least one anti-cancer agent.
62 . The method of any one of claims 48 to 61 , wherein said compound of formula I and said inhibitor of said combination are administered simultaneously or sequentially.
63 . The method of any one of claims 48 to 62 , wherein said compound of formula I is administered 2 to 3 times per week.
64 . The method of any one of claims 48 to 63 , wherein said compound of formula I is administered daily.
65 . The method of any one of claims 48 to 64 , wherein said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor and said compound of formula I are concomitantly administered on day 1 of an administration regimen.
66 . The method of any one of claims 48 to 64 , wherein said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor and said compound of formula I are administered to said patient as a regimen.
67 . The method of claim 66 , wherein said regimen is repeated until disease progression or unacceptable toxicity.
68 . The method of claim 66 , wherein said regimen comprises a rest period of at least 1 day between consecutive administration periods.
69 . The method of any one of claims 48 to 68 , wherein said compound of formula I is administered 2 to 3 times per week and said PD-L1 inhibitor, PD-1 inhibitor, CTLA-4 inhibitor, and/or CD276 inhibitor is administered every 2 to 3 weeks.
70 . The method of claim 69 , wherein said compound of formula I of said combination is administered once a day (“QD”) for 21 days in said regimen and said inhibitor antibody is administered every 2 to 3 weeks.